If Approved, AJOVY will be the First and Only Anti-CGRP Treatment with Quarterly and Monthly Dosing Options in the European Union
JERUSALEM, Israel I February 1, 2019 I Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting a marketing authorization for AJOVY® (fremanezumab) 225 mg solution for injection in pre-filled syringe for the prophylaxis of migraine in adults who have at least four migraine days per month. If approved by the European Commission (EC), AJOVY, a humanized monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, will be the first and only anti-CGRP treatment in the European Union (EU) with both quarterly and monthly dosing options.
Migraine is a disabling neurological disease often accompanied by nausea, vomiting, photophobia, phonophobia and changes in vision.1 Globally, there are approximately one billion people affected by migraine2, with more than 50 million people suffering from the disease across Europe.3 It is estimated that the total annual cost of migraine in Europe is €111 billion.4
“We are very pleased to report a positive opinion by the CHMP,” said Richard Daniell, Executive Vice President, European Commercial at Teva. “This is another important milestone for us and the migraine community as a whole. We hope to expand the availability of AJOVY to the EU so that eligible patients can potentially benefit from the flexibility AJOVY offers through quarterly and monthly dosing options.”
The positive CHMP opinion is based on the review of a Marketing Authorization Application (MAA) that included efficacy and safety data from the HALO clinical development program. The program evaluated fremanezumab in two pivotal Phase III clinical trials that enrolled patients with disabling migraine and studied fremanezumab as a prophylaxis of migraine in adults. In these trials, patients treated with fremanezumab had a significantly greater reduction in migraine days compared to placebo. Adverse drug reactions (ADRs) observed with AJOVY were mostly mild to moderate, short-lasting skin reactions around the injection area: pain, hardening, redness, itching and rash at the injection site.
“Migraine is the most prevalent disabling neurological disease in Europe,” said Professor Peter J. Goadsby, MD, PhD, Professor of Neurology at King’s College, London. “It is the second most common cause of years lost to disability in the world, interrupting patients during their most active and productive years. Migraine disrupts their work and family lives at a time when others rely on them the most. Many patients have to live in fear of their next attack; the most disabled have chronic migraine, experiencing 15 or more days of illness per month. Fremanezumab is an anti-CGRP monoclonal antibody (mAb) specifically developed for migraine, and if approved for use in the EU, it will offer an additional treatment option for patients and more flexibility in managing their condition.”
The positive CHMP opinion is a formal recommendation to grant the marketing authorization for AJOVY in the EU. The recommendation will now be reviewed by the EC, which has authority to approve medicines for use in the 28 countries of the EU. A final decision is expected in the first half of 2019.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 45,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com.
1 IHS classification – Migraine classification criteria.
2 Migraine Facts, Migraine Research Foundation. Available at https://migraineresearchfoundation.org/about-migraine/migraine-facts/. Accessed January 2019.
3 Headache. EAN. Available at: https://www.ean.org/index.php?id=2796. Accessed January 2019.
4 Linde M1 Gustavsson A, Stovner LJ et al. 2011. The cost of headache disorders in Europe: the Eurolight project. [Online] Available from: https://www.ncbi.nlm.nih.gov/pubmed/22136117. Accessed January 2019.
SOURCE: Teva Pharmaceutical Industries
Post Views: 40
If Approved, AJOVY will be the First and Only Anti-CGRP Treatment with Quarterly and Monthly Dosing Options in the European Union
JERUSALEM, Israel I February 1, 2019 I Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting a marketing authorization for AJOVY® (fremanezumab) 225 mg solution for injection in pre-filled syringe for the prophylaxis of migraine in adults who have at least four migraine days per month. If approved by the European Commission (EC), AJOVY, a humanized monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, will be the first and only anti-CGRP treatment in the European Union (EU) with both quarterly and monthly dosing options.
Migraine is a disabling neurological disease often accompanied by nausea, vomiting, photophobia, phonophobia and changes in vision.1 Globally, there are approximately one billion people affected by migraine2, with more than 50 million people suffering from the disease across Europe.3 It is estimated that the total annual cost of migraine in Europe is €111 billion.4
“We are very pleased to report a positive opinion by the CHMP,” said Richard Daniell, Executive Vice President, European Commercial at Teva. “This is another important milestone for us and the migraine community as a whole. We hope to expand the availability of AJOVY to the EU so that eligible patients can potentially benefit from the flexibility AJOVY offers through quarterly and monthly dosing options.”
The positive CHMP opinion is based on the review of a Marketing Authorization Application (MAA) that included efficacy and safety data from the HALO clinical development program. The program evaluated fremanezumab in two pivotal Phase III clinical trials that enrolled patients with disabling migraine and studied fremanezumab as a prophylaxis of migraine in adults. In these trials, patients treated with fremanezumab had a significantly greater reduction in migraine days compared to placebo. Adverse drug reactions (ADRs) observed with AJOVY were mostly mild to moderate, short-lasting skin reactions around the injection area: pain, hardening, redness, itching and rash at the injection site.
“Migraine is the most prevalent disabling neurological disease in Europe,” said Professor Peter J. Goadsby, MD, PhD, Professor of Neurology at King’s College, London. “It is the second most common cause of years lost to disability in the world, interrupting patients during their most active and productive years. Migraine disrupts their work and family lives at a time when others rely on them the most. Many patients have to live in fear of their next attack; the most disabled have chronic migraine, experiencing 15 or more days of illness per month. Fremanezumab is an anti-CGRP monoclonal antibody (mAb) specifically developed for migraine, and if approved for use in the EU, it will offer an additional treatment option for patients and more flexibility in managing their condition.”
The positive CHMP opinion is a formal recommendation to grant the marketing authorization for AJOVY in the EU. The recommendation will now be reviewed by the EC, which has authority to approve medicines for use in the 28 countries of the EU. A final decision is expected in the first half of 2019.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 45,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com.
1 IHS classification – Migraine classification criteria.
2 Migraine Facts, Migraine Research Foundation. Available at https://migraineresearchfoundation.org/about-migraine/migraine-facts/. Accessed January 2019.
3 Headache. EAN. Available at: https://www.ean.org/index.php?id=2796. Accessed January 2019.
4 Linde M1 Gustavsson A, Stovner LJ et al. 2011. The cost of headache disorders in Europe: the Eurolight project. [Online] Available from: https://www.ncbi.nlm.nih.gov/pubmed/22136117. Accessed January 2019.
SOURCE: Teva Pharmaceutical Industries
Post Views: 40
